Article

<i>In silico</i> Exploration Natural Compounds for the Discovery of Novel DNMT3A Inhibitors as Potential Therapeutic Agents for Acute Myeloid Leukemia

2024-08-29

Abstract excerpt

<h4>ABSTRACT</h4> Aberrant DNA methylation, a hallmark of acute myeloid leukemia (AML), is catalyzed by DNA methyltransferase 3A (DNMT3A). Approximately 20-30% of AML patients harbor DNMT3A mutations, leading to disrupted DNA methylation patterns and leukemogenesis. To identify potential therapeutic interventions, this study employed computational drug discovery. A pharmacophore model was constructed and utilized...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: abf6b576-f88b-5376-997f-3f567095108f
DOI: 10.1101/2024.08.28.610083

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>In silico</i> Exploration Natural Compounds for the Discovery of Novel DNMT3A Inhibitors as Potential Therapeutic Agents for Acute Myeloid LeukemiaDOI 10.1101/2024.08.28.610083Read

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: an <i>in silico</i> approachSemantic proximity Read

Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia TreatmentSemantic proximity Read

Computationally Guided Design of BCR-ABL Tyrosine Kinase InhibitorsSemantic proximity Read

First-in-Class Allosteric Inhibitors of DNMT3A Disrupt Protein-Protein Interactions and Induce Acute Myeloid Leukemia Cell Differentiation.Semantic proximity Read

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AMLSemantic proximity Read

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia.Semantic proximity Read

De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment.Semantic proximity Read

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AMLSemantic proximity Read

Evolutionary Conservation of Human DNA Methyltransferase 3 Alpha (Dnmt3a) Gene in Acute Myeloid Leukemia (Aml): A Computational StudySemantic proximity Read

Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulationSemantic proximity Read

Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.Semantic proximity Read

Computational investigation unveils pathogenic LIG3 non-synonymous mutations and therapeutic targets in acute myeloid leukemiaSemantic proximity Read